Stock ZIM ZIMMER BIOMET HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zimmer Biomet Holdings, Inc. Deutsche Boerse AG

Equities

ZIM

US98956P1021

Medical Equipment, Supplies & Distribution

Market Closed - Deutsche Boerse AG
Other stock markets
 07:03:25 28/06/2024 BST 		5-day change 1st Jan Change
100.9 EUR +0.35% Intraday chart for Zimmer Biomet Holdings, Inc. +2.29% -8.06%
06-20 Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors CI
06-12 Zimmer Biomet Enters Co-Marketing Deal With RevelAi Health MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 30,787 31,940 26,540 26,756 25,433 22,328 - -
Enterprise Value (EV) 1 38,390 39,264 33,130 32,077 30,785 26,652 25,321 24,845
P/E ratio 27.4 x -230 x 66.5 x 116 x 24.9 x 22.3 x 19.2 x 16.6 x
Yield 0.64% 0.62% 0.76% 0.75% 0.79% 0.89% 0.9% 0.95%
Capitalization / Revenue 3.86 x 4.55 x 3.39 x 3.86 x 3.44 x 2.88 x 2.75 x 2.64 x
EV / Revenue 4.81 x 5.59 x 4.23 x 4.62 x 4.16 x 3.43 x 3.12 x 2.94 x
EV / EBITDA 14.7 x 19.2 x 13.3 x 14 x 12.4 x 9.97 x 8.98 x 8.91 x
EV / FCF 36.1 x 49.4 x 32.3 x 35.2 x 31.5 x 25.2 x 17.4 x 15.4 x
FCF Yield 2.77% 2.03% 3.1% 2.84% 3.18% 3.97% 5.75% 6.49%
Price to Book 2.49 x 2.62 x 2.1 x 2.22 x 2 x 1.67 x 1.52 x 1.44 x
Nbr of stocks (in thousands) 205,684 207,278 208,909 209,852 208,981 205,728 - -
Reference price 2 149.7 154.1 127.0 127.5 121.7 108.5 108.5 108.5
Announcement Date 04/02/20 05/02/21 07/02/22 03/02/23 08/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7,982 7,024 7,836 6,940 7,394 7,761 8,118 8,459
EBITDA 1 2,610 2,044 2,487 2,293 2,477 2,673 2,820 2,788
EBIT 1 2,188 1,609 2,035 1,894 2,087 2,244 2,379 2,518
Operating Margin 27.42% 22.91% 25.97% 27.29% 28.22% 28.91% 29.3% 29.76%
Earnings before Tax (EBT) 1 905.8 -274.4 418.4 403.5 1,067 1,207 1,470 1,534
Net income 1 1,132 -138.9 401.6 231.4 1,024 997.6 1,199 1,341
Net margin 14.18% -1.98% 5.12% 3.33% 13.85% 12.85% 14.76% 15.85%
EPS 2 5.470 -0.6700 1.910 1.100 4.880 4.874 5.661 6.542
Free Cash Flow 1 1,063 795.3 1,025 910 978.8 1,059 1,455 1,612
FCF margin 13.31% 11.32% 13.09% 13.11% 13.24% 13.64% 17.92% 19.06%
FCF Conversion (EBITDA) 40.72% 38.91% 41.23% 39.68% 39.51% 39.62% 51.59% 57.82%
FCF Conversion (Net income) 93.92% - 255.33% 393.26% 95.59% 106.14% 121.39% 120.23%
Dividend per Share 2 0.9600 0.9600 0.9600 0.9600 0.9600 0.9641 0.9744 1.032
Announcement Date 04/02/20 05/02/21 07/02/22 03/02/23 08/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 2,038 1,663 1,782 1,670 1,825 1,831 1,870 1,754 1,940 1,889 1,942 1,865 2,066 1,980 2,034
EBITDA 1 642.2 542.2 597.9 748 613.9 618.7 613.6 560 684.8 635.9 658.3 623 734.5 673.9 701.7
EBIT 1 527 439.2 498.2 439.5 516.9 520.3 514.3 463.8 588.5 539.4 552.9 522.1 629.2 569 587
Operating Margin 25.86% 26.41% 27.96% 26.32% 28.32% 28.42% 27.51% 26.45% 30.33% 28.55% 28.47% 27.99% 30.46% 28.74% 28.87%
Earnings before Tax (EBT) -138.7 101.2 199.5 478.3 -74.8 286.8 276.8 219.2 284.4 215.1 - - - - -
Net income 1 -84 14.2 153.7 361.9 -130.5 232.5 209.6 162.7 419.2 172.4 259.5 233.6 319.5 310 315
Net margin -4.12% 0.85% 8.63% 21.67% -7.15% 12.7% 11.21% 9.28% 21.61% 9.13% 13.36% 12.53% 15.47% 15.66% 15.49%
EPS 2 -0.4000 0.0700 0.7300 1.720 -0.6200 1.110 1.000 0.7700 2.010 0.8400 1.237 1.131 1.557 1.325 1.478
Dividend per Share 2 0.2400 0.2400 0.2400 0.2400 0.2400 0.2400 0.2400 - 0.2400 - 0.2436 0.2431 0.2432 0.2491 0.2488
Announcement Date 07/02/22 03/05/22 02/08/22 02/11/22 03/02/23 02/05/23 01/08/23 07/11/23 08/02/24 02/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 7,604 7,324 6,590 5,321 5,352 4,324 2,993 2,517
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.913 x 3.583 x 2.65 x 2.32 x 2.161 x 1.618 x 1.061 x 0.9029 x
Free Cash Flow 1 1,063 795 1,025 910 979 1,059 1,455 1,612
ROE (net income / shareholders' equity) 13.7% 9.61% 12.5% 11.7% 12.9% 12.9% 12.9% 15.2%
ROA (Net income/ Total Assets) 6.67% 4.82% 6.48% 6.51% 7.44% 7.72% 8.15% 12.7%
Assets 1 16,965 -2,883 6,202 3,555 13,756 12,917 14,703 10,597
Book Value Per Share 2 60.10 58.70 60.60 57.50 60.70 65.00 71.30 75.20
Cash Flow per Share 2 7.670 5.820 7.130 6.450 7.540 9.960 11.10 14.10
Capex 1 523 409 474 446 603 571 594 618
Capex / Sales 6.55% 5.83% 6.05% 6.43% 8.15% 7.35% 7.31% 7.3%
Announcement Date 04/02/20 05/02/21 07/02/22 03/02/23 08/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Zimmer Biomet Holdings, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
108.5 USD
Average target price
136.4 USD
Spread / Average Target
+25.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.60% 181B
MEDTRONIC PLC Stock Medtronic plc
-4.45% 101B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.15% 67.54B
DEXCOM, INC. Stock DexCom, Inc.
-8.63% 45.09B
CENCORA, INC. Stock Cencora, Inc.
+9.70% 44.37B
HOYA CORPORATION Stock Hoya Corporation
+6.13% 40.7B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.22% 29.85B
TERUMO CORPORATION Stock Terumo Corporation
+14.80% 24.49B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-6.46% 23.99B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. ZBH Stock
  4. ZIM Stock
  5. Financials Zimmer Biomet Holdings, Inc.